Nasopharyngeal carcinoma

被引：295

作者：

Chan, ATC ^{[1
]}

Teo, PML ^{[1
]}

Johnson, PJ ^{[1
]}

机构：

[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Sir YK Pao Canc Ctr, Shatin, Hong Kong, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2002年 / 13卷 / 07期

关键词：

Epstein-Barr virus; nasopharyngeal carcinoma; review; treatment;

D O I：

10.1093/annonc/mdf179

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Nasopharyngeal carcinoma (NPC) is endemic in southern China where genetic abnormalities and Epstein-Barr virus (EBV) infection are critical in the pathogenesis of the disease, Circulating EBV-DNA has been shown to improve prognostication and monitoring of NPC patients. Radiotherapy is the mainstay treatment for early disease and concurrent cisplatin/radiotherapy has been demonstrated to prolong survival in locoregionally advanced disease. Ongoing studies of targeting agents and immunotherapeutic approaches may further improve treatment results.

引用

页码：1007 / 1015

页数：9

共 61 条

[41] Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma:: three meta-analyses of updated individual data [J].

Pignon, JP ;

Bourhis, J ;

Domenge, C ;

Designé, L .

LANCET, 2000, 355 (9208) :949-955

[42]

POON TCW, 2001, P AM SOC CLIN ONCOL, V20

[43] PROGNOSTIC-SIGNIFICANCE OF KERATINIZATION IN NASOPHARYNGEAL CARCINOMA [J].

REDDY, SP ;

RASLAN, WF ;

GOONERATNE, S ;

KATHURIA, S ;

MARKS, JE .

AMERICAN JOURNAL OF OTOLARYNGOLOGY, 1995, 16 (02) :103-108

[44] ADJUVANT CHEMOTHERAPY WITH VINCRISTINE, CYCLOPHOSPHAMIDE, AND DOXORUBICIN AFTER RADIOTHERAPY IN LOCAL-REGIONAL NASOPHARYNGEAL CANCER - RESULTS OF A 4-YEAR MULTICENTER RANDOMIZED STUDY [J].

ROSSI, A ;

MOLINARI, R ;

BORACCHI, P ;

DELVECCHIO, M ;

MARUBINI, E ;

NAVA, M ;

MORANDI, L ;

ZUCALI, R ;

PILOTTI, S ;

GRANDI, C ;

AMBROSINI, G ;

CELLINI, N ;

CHIAVACCI, A ;

COLOMBO, A ;

DALFIOR, S ;

DEMARIA, D ;

FELCI, U ;

GABRIELE, P ;

LADDAGA, M ;

MAGNO, L ;

MARZIANO, C ;

OLMI, P ;

PRINO, A ;

RONCORONI, L ;

TORRETTA, A ;

ZAMPI, G ;

ZORAT, PL ;

DEPALO, G .

JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (09) :1401-1410

[45]

SHANMUGARATNAM K, 1993, CANCER-AM CANCER SOC, V71, P2689, DOI 10.1002/1097-0142(19930415)71:8<2689::AID-CNCR2820710843>3.0.CO

[46]

2-H

[47] Phase I/II study of the CAPABLE regimen for patients with poorly differentiated carcinoma of the nasopharynx [J].

Siu, LL ;

Czaykowski, PM ;

Tannock, IF .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (07) :2514-2521

[48] Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma [J].

Tan, EH ;

Khoo, KS ;

Wee, J ;

Fong, KW ;

Lee, KS ;

Lee, KM ;

Chua, ET ;

Tan, T ;

Khoo-Tan, HS ;

Yang, TL ;

Au, E ;

Tao, M ;

Ong, YK ;

Chua, EJ .

ANNALS OF ONCOLOGY, 1999, 10 (02) :235-237

[49] Significant prognosticators after primary radiotherapy in 903 nondisseminated nasopharyngeal carcinoma evaluated by computer tomography [J].

Teo, P ;

Yu, P ;

Leung, SF ;

Kwan, WH ;

Yu, KH ;

Choi, P ;

Johnson, PJ .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 36 (02) :291-304

[50] Intracavitary brachytherapy significantly enhances local control of early T-stage nasopharyngeal carcinoma: The existence of a dose-tumor-control relationship above conventional tumoricidal dose [J].

Teo, PML ;

Leung, SF ;

Lee, WY ;

Zee, B .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 46 (02) :445-458

← 1 2 3 4 5 6 7 →